Author at Microdose

Elisabetta Fato

A native Italian, I currently study Biomedical Sciences at Queen Mary University of London. I have been closely following the latest updates in psychedelics research since the beginning of my undergraduate studies. My passion for science and writing allowed me to write articles published by the British Pharmacological Society and Neurosight, now available on their online magazine and blog respectively. In the future, I am determined to pursue a research career in Neuroscience and Neuropsychopharmacology for the study of Human Consciousness, and I truly believe in the potential of psychedelics as tools that could be used for the investigation of its nature.

Science

8 Jun 2022

Psychedelics for a Healthier Mind and Lifestyle

Psychedelics have been shown to effectively deal with mental health issues, could they be used as prevention by acting on our general lifestyle and everyday behaviour?...

By Elisabetta Fato

Science

1 Jun 2022

A Deeper Look at DMT Trials & Studies

Preliminary results from Phase I clinical trials on DMT for major depressive disorder (MDD) support the safety and tolerability of the compound....

By Elisabetta Fato

Science

9 May 2022

Science Feature: Psilocybin For Anorexia

As depressive and anxiety states often co-occur with eating disorders such as anorexia nervosa, research is now being conducted to find out whether psychedelics could be employed for the treatment...

By Elisabetta Fato

Science

1 Apr 2022

Connecting to Nature Through Psychedelics

Many of the ecological initiatives we still celebrate today, like Earth Day, have their origins in the popularity of psychedelics...

By Elisabetta Fato

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

1 Feb 2022

Science Feature: Re-Inventing Creativity With Psychedelics

How are psychedelics connected to the brain mechanisms to create creativity? What is the evidence of their beneficial effects on creative processes? Could these drugs help scientists grasp the nature...

By Elisabetta Fato

Science

28 Dec 2021

Psychedelics: a non-addictive hope for addiction

Clinical trials testing psychedelics’ effects on tobacco and alcohol addiction, as well as on other substance use disorders, are currently being conducted to investigate their effectiveness at a more global...

By Elisabetta Fato

Science

8 Dec 2021

Science Feature: A Look at the 5HT-2A Receptor

Spend enough time in the psychedelic medicine space — as either an investor or advocate or enthusiast — and you’ll inevitably become familiar with terms like the 5HT-2A receptor....

By Elisabetta Fato

Follow us on social

Latest News

You Might Also Like

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts

10 Oct 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma?

In the wake of Gilgamesh’s billion-dollar exit, a new wave of companies is emerging, smaller, stealthier, and far more scientifically disciplined than their first-wave predecessors. Their mission: harness the therapeutic...

By Madison Roberts

WordPress Ads